Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Clinical trial NCT06635824 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06635824
- Sponsor
- Genmab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-25
- Primary completion
- 2027-07-30
- Enrollment
- 191
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.